Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system
Seattle, US
Size (employees)
162 (est)
Omeros is headquartered in Seattle, US

Key People at Omeros

Gregory A. Demopulos

Gregory A. Demopulos

Chairman and Chief Executive Officer
Wayne Wager

Wayne Wager

Timothy M. Duffy

Timothy M. Duffy

Vice President, Business Development

Omeros Office Locations

Omeros has an office in Seattle
Seattle, US (HQ)
201 Elliott Ave

Omeros Metrics

Omeros Financial Metrics

Omeros's revenue was reported to be $41.6 m in 2016

Revenue (Y, 2016)

$41.6 m

Revenue growth (Y, 2015 - Y, 2016), %


Gross profit (Y, 2016)

$40.2 m

Gross profit margin (Y, 2016), %


Net income (Y, 2016)

($66.7 m)

EBIT (Y, 2016)

($54.3 m)

Market capitalization (19-May-2017)

$706.1 m

Closing share price (19-May-2017)


Cash (31-Dec-2016)

$2.2 m
Omeros's current market capitalization is $706.1 m.
FY, 2013FY, 2014FY, 2015Y, 2016


$1.6 m$539 k$13.5 m$41.6 m

Revenue growth, %


Cost of goods sold

$1 m$1.4 m

Gross profit

$12.5 m$40.2 m

Gross profit Margin, %


Operating expense total

$52.1 m$70.5 m$84.7 m$95.9 m


($50.5 m)($70 m)($71.2 m)($54.3 m)

EBIT margin, %


Interest expense

($2.4 m)($3.5 m)($3.6 m)($7.8 m)

Net Income

($39.8 m)($73.7 m)($75.1 m)($66.7 m)
FY, 2013FY, 2014FY, 2015FY, 2016


$1.4 m$354 k$1.4 m$2.2 m

Accounts Receivable


$337 k$472 k$1.1 m

Current Assets

$14.8 m$9.2 m$37.1 m$60.3 m


$939 k$782 k$951 k$1.2 m

Total Assets

$16.5 m$11.1 m$49 m$67.3 m

Accounts Payable

$2.3 m$4.9 m$6.4 m$2.5 m

Current Liabilities

$11.9 m$18.4 m$16.3 m$16.1 m

Additional Paid-in Capital

$235.7 m$285.1 m$376.5 m$432 m

Retained Earnings

($254.4 m)($328 m)($403.1 m)($469.9 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($39.8 m)($73.7 m)($75.1 m)($66.7 m)

Depreciation and Amortization

$302 k$326 k$209 k$300 k

Accounts Receivable


$96 k($656 k)

Accounts Payable

$4.2 m($319 k)

Cash From Operating Activities

($29.7 m)($58 m)($65.2 m)($51.5 m)

Purchases of PP&E

($204 k)

Cash From Investing Activities

$7.9 m$6.2 m($20.6 m)($16.3 m)

Long-term Borrowings

($1.5 m)

Cash From Financing Activities

$21.7 m$50.9 m$86.8 m$68.7 m

Interest Paid

$1.7 m$2.7 m$4.2 m$5.3 m
Y, 2016


$256.9 k

Omeros Market Value History

Omeros Online Presence

Omeros News

Omeros Company Life

You may also be interested in